REVERSIBILITY OF LIPOATROPHY IN HIV-INFECTED PATIENTS TAKING ANTIRETROVIRAL THERAPY: A COHORT STUDY WITH ULTRASOUND ASSESSMENT.

Autor: Šoštarić Zadro A; Dr Fran Mihaljević University Hospital for Infectious Diseases, Zagreb, Croatia; University of Zagreb, School of Medicine, Zagreb, Croatia., Višković K; Dr Fran Mihaljević University Hospital for Infectious Diseases, Zagreb, Croatia; University of Zagreb, School of Medicine, Zagreb, Croatia., Begovac J; Dr Fran Mihaljević University Hospital for Infectious Diseases, Zagreb, Croatia; University of Zagreb, School of Medicine, Zagreb, Croatia.
Jazyk: angličtina
Zdroj: Acta clinica Croatica [Acta Clin Croat] 2022 Mar; Vol. 61 (1), pp. 11-18.
DOI: 10.20471/acc.2022.61.01.02
Abstrakt: The aim of this study was to characterize and compare changes in subcutaneous fat in the malar, brachial and crural region in a cohort of HIV-infected patients taking antiretroviral therapy. This prospective longitudinal study included 77 patients who were selected from the initial cohort evaluated in 2007 and 2008. We examined reversibility of lipoatrophy measured by ultrasound over at least five-year period and factors related to its reversibility. All 46 patients who used stavudine switched from stavudine to another combination. Of 58 patients on zidovudine, 16 (28%) were on a zidovudine based regimen at the second follow up. There was evidence for subcutaneous fat increase in the malar area (p<0.001) and no increase in the brachial and crural areas. Patients who were smokers and had poor adherence to the Mediterranean diet had a thinner malar area at the follow up measurement (p=0.030) and smaller increase in subcutaneous malar fat compared to others (p=0.040). Our study suggested that modest increase of subcutaneous fat in malar area coincided with stopping stavudine and fewer usage of zidovudine. Lifestyle with non-adherence to the Mediterranean diet and smoking were associated with a smaller increase in subcutaneous malar fat.
Databáze: MEDLINE
Externí odkaz: